No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
BIVI250117C5000
- 0.00
- 0.000.00%
15min DelayClose Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV142.72%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
BioVie Files to Sell 7.71M Shares of Common Stock for Holders
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie | 10-Q: Q1 2025 Earnings Report
Express News | BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
Express News | Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
(BIVI) - Analyzing BioVie's Short Interest